Published in Hospital and Nursing Home Week, August 7th, 2008
Two Phase 1 studies evaluated (i) plasma concentrations from single rising doses in 30 young and 12 elderly volunteers and (ii) 14-day chronic dosing in a second set of 12 young and 12 elderly volunteers. No significant adverse events were registered in single doses from 5 to 405 mg for young subjects, in single doses from 45 to 135 mg for elderly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.